Editas Medicine Inc
Fermé
SecteurSoins de santé
2.71 2.65
Résumé
Variation du prix de l'action
24h
Min
2.69
Max
2.71
Revenu | 6.8M -18M |
|---|---|
Ventes | 9.1M 12M |
BPA | -0.15 |
Marge bénéficiaire | -153.322 |
Employés | 87 |
EBITDA | 3.9M -20M |
Prochains Résultats | 9 nov. 2026 |
|---|
Capitalisation Boursière | 89M 496M |
|---|---|
Ouverture précédente | 0.06 |
Clôture précédente | 2.71 |
Sentiment de l'Actualité
By Acuity
50%
50%
126 / 339 Classement par Healthcare
Editas Medicine Inc Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
Actualités Associées
Comparaison
Variation de prix
Editas Medicine Inc prévision
Sentiment
By Acuity
126 / 339Classement par Soins de santé
Sentiment de l'Actualité
Neutral
Volatilité
Inférieur à la moyenne
Changement du Volume d'Actualités (RCV)
Inférieur à la moyenne
Éléments financiers
Frais Généraux et Administratifs
Dépenses d'exploitation
Résultat avant impôt
Ventes
Coût des ventes
Marge brute des ventes
Charges d'intérêt sur la dette
EBITDA
Bénéfice d'exploitation
$
À Propos Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.